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Editorial
Postdischarge Assessment After a Heart
Failure Hospitalization
The Next Step Forward
Marco Metra, MD; Mihai Gheorghiade, MD; Robert O. Bonow, MD; Livio Dei Cas, MD
Heart failure (HF) is the most frequent cause of hospital-ization for patients 65 years of age.1–5 More than 1
million patients are admitted to the hospital with HF each
year in the United States, and this number is likely to increase
because of aging of the general population, improved survival
after acute cardiovascular conditions, and prevention of
sudden cardiac death. Hospitalization for HF is one of the
most powerful independent risk factors for death among
patients with HF. Mortality during the initial hospitalization
ranges from 6% to 7% in Europe to 3% to 4% in the United
States, depending on the length of hospital stay.1,2 Poor
outcomes have universally been shown after discharge, with
60- to 90-day mortality rates of 5% to 15% and hospital
readmission rates of 30%.1,6,7 Depending on the duration of
the first hospitalization and on the number of previous
hospitalizations, the risk of dying after a hospitalization for
HF is increased from 4-fold to 16-fold compared with before
the hospitalization.8
Article see p 1806
Whereas the prognosis of patients with chronic HF has
improved in recent years, there has been no change in the
high risk of death or rehospitalization after an HF hospital-
ization.6,9–11 This has multiple causes. First, the hospitaliza-
tion for HF may be the expression of end-stage HF. In these
patients, all therapies have already been tried and have
become ineffective or were not tolerated. There are no
chances to improve their symptoms and prognosis except
with the use of assist devices or heart transplantation. These
patients, however, are only a small proportion, 5%, of all
the patients hospitalized for HF. An improvement in out-
comes is possible in the others.1,12 In addition to the lack of
new therapies, incomplete relief from fluid overload, insuffi-
cient patient education, lack of implementation of evidence-
based therapies, and poor postdischarge follow-up planning
are among the main causes of their poor outcomes.2–4
The transition from the in-hospital to the outpatient setting
involves not only changes in the physician(s) providing care
but also modifications in diet, self-dependence in the admin-
istration of new and complex drug therapies, demands for
more physical activity, and confrontation with familial and
social stresses. All of these factors make the early postdis-
charge period a vulnerable phase. Changes in fluid status
and/or renal function frequently occur, and outcomes may be
deeply affected.5,13 In addition, uptitration of lifesaving ther-
apies such as neurohormonal antagonists may require many
weeks, and thus only an early postdischarge follow-up may
allow its completion. Postdischarge assessment is now
deemed an essential component of the treatment of the
patients hospitalized for HF.2–4 It directly follows the 3
earlier phases of evaluation and management of the patients
with acute HF, summarized as the early or emergency
department (ED) phase, the in-hospital phase, and the predis-
charge phase.2,7,13 However, it remains to be established who
should perform the postdischarge assessment, in which pa-
tients and when it should take place, and what should be its
components.2–4
In this issue of Circulation, Lee et al14 relate the type of
transition care with the outcomes of 10 599 patients with HF
evaluated at EDs in Ontario, Canada, between April 1, 2004,
and March 31, 2007. Data obtained with the National Am-
bulatory Care Reporting System clearly demonstrate the
benefits of a postdischarge assessment performed by both the
primary care (PC) physician and the cardiologist compared
with the lack of any physician assessment but also with
PC-only practice.
Who Should Perform
Postdischarge Assessment?
The study by Lee et al provides answers to this question. Lee
et al subdivided patients into 4 groups according to their
postdischarge care: no physician visit (n1990), PC only
(n6596), cardiologist only (n535), and collaborative care
including a PC physician and a cardiologist (n1478).
Internal medicine specialists who provided cardiology care
were considered cardiac specialists. Compared with PC,
collaborative care patients were more likely to undergo an
assessment of left ventricular function (57.4% versus 28.7%),
noninvasive stress testing (20.1% versus 7.8%), and cardiac
catheterization (11.6% versus 2.7%). They were also more
likely to be treated with angiotensin-converting enzyme
inhibitors (58.8% versus 54.6%), angiotensin receptor block-
ers (22.7% versus 18.1%), -blockers (63.4% versus 48.0%),
spironolactone (19.8% versus 12.7%), and loop diuretics. In a
propensity-matched model, PC was associated with signifi-
cantly lower mortality compared with no physician evalua-
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tion (P0.001), thus showing the benefits of postdischarge
follow-up. Collaborative care further reduced mortality com-
pared with PC (P0.001). Similar results were found for the
composite end points of death, ED visits, and HF rehospital-
ization (the Figure), as well as for all-cause ED visits,
rehospitalizations, and deaths.14
Lee et al are to be commended for their comprehensive
evaluation of such a complex reality as post-ED care follow-
up. Their study shows the need and benefits of a collaborative
approach including both the PC physician and the cardiolo-
gist after an ED admission for acute HF with a magnitude of
effect that is comparable to that shown with neurohormonal
antagonists or devices prescribed to treat HF. The present
study also explores the potential mechanisms of this benefi-
cial effect, including greater performance of diagnostic tests
and implementation of lifesaving therapies. These data are
consistent with previous studies comparing the treatment of
patients with HF by PC physicians, internists, and cardiolo-
gists during either the in-hospital or the outpatient phase2,3,15
and extend them to the early post-hospitalization phase,
showing also the importance of this follow-up.
A potential limitation of the present study is the exclusion
of early postdischarge events in order to have a comparison
group of patients assessed by the PC physician. In another
study from the same authors, ED visits for HF were followed
by a high early mortality rate, with 4.0% of patients dying
within 30 days and 1.3% in the first 7 days.16 In addition, ED
visits, but not hospitalizations, were analyzed in this study.
This is pertinent because 30% of patients who underwent
ED evaluation for HF were discharged without hospital
admission in a similar cohort of patients.16 The present study
may lack data regarding clinical characteristics, comorbidi-
ties, and in-hospital course of the patients, so meaningful
variables may not have been included in the propensity
analysis. These limitations are acknowledged by the authors
and are expected in studies based on the examination of large
registries.
Despite its rationale, postdischarge assessment has been
examined only recently.5,7 Hernandez et al17 have recently
assessed the relationship between early physician follow-up
and 30-day outcomes among 30 136 Medicare beneficiaries
hospitalized for HF. Consistent with the study of Lee et al,
Table. Components of Early Postdischarge Follow-Up
Action
Expected Outcomes
Prevention
of Fluid
Overload
Improvement
in Symptoms
Improvement in
Prognosis
Education
Diet   
Exercise  
Medications (benefits,
side effects)
  
Weight monitoring   
Detection and treatment
of worsening symptoms
  
Assessment of compliance
Medical therapy   
Nonpharmacological
prescriptions (diet,
exercise, weight
monitoring)
  
Assessment of prognostic variables
Clinical
Signs of congestion:
pulmonary rales,
jugular venous
congestion,
hepatomegaly,
peripheral edema
  
Blood pressure  ? 
Heart rate ?  (?) 
Orthostatic test  ? ?
Valsalva maneuver  ? ?
ECG
QRS duration, indication
to CRT
  
Atrial fibrillation,
tachyarrhythmias
 (?)  
Laboratory examinations
Myocardial viability*    (?)
Natriuretic peptides   
Renal function
and electrolytes
 /0 / (?)
Anemia and/or
iron deficiency
?  ?
Devices for fluid status
monitoring
   (?)
Optimization of medical treatment
Changes in diuretic doses
according to fluid status
   (?)
Initiation or uptitration
of evidence-based
therapies (renin-angiotensin-
aldosterone antagonists,
-blockers, digoxin)
  
CRT when indicated   
ICD when indicated 0 0 
Coronary revascularization
when indicated
   (?)
Other surgical procedures
(eg, mitral valve surgery)
  ?
CRT indicates cardiac resynchronization therapy; ICD, implantable cardio-
verter defibrillator.
*Viable but dysfunctional and potentially salvageable myocardium.
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Figure. Mortality rates (left) and rates of deaths, ED visits, and
hospitalizations for HF (right) in the patients with different post-
discharge follow-up. Collaborative care indicates care by both a
PC physician and a cardiologist. *P0.004; **P0.001.
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discharge from hospitals in which a greater proportion of
patients received early follow-up evaluation was indepen-
dently associated with lower rates of all-cause readmissions,
although mortality was not affected.17
When Should the Postdischarge Assessment
Be Performed?
As outlined above, the vulnerable phase occurs just after
discharge from hospital. The incidence of death or rehospi-
talizations sharply increases early after discharge and gradu-
ally decreases thereafter, following an almost exponential
pattern.8,18 This suggests that an early assessment, ie, 1 to 2
weeks after discharge, should yield the greatest benefit.
Which Patients?
The number of patients hospitalized for HF is so large that a
postdischarge assessment strategy cannot be proposed for all.
Ideally, postdischarge assessment should include only the
patients who, in the predischarge phase, are found to be at
high risk of cardiac events. Simple but powerful predictors of
postdischarge events include blood pressure, QRS duration,
renal dysfunction, serum levels of sodium, natriuretic pep-
tides and troponin, and other comorbidities.1,5,19 The hospital
length of stay and the number of previous rehospitalizations
are also major prognostic variables.8,9,18
What Should the Postdischarge
Assessment Accomplish?
The postdischarge evaluation provides the opportunity to
reassess fluid status, to provide additional patient education,
to review medications and adjust their doses, and to plan for
additional diagnostic and interventional procedures. Goals
may target multiple mechanisms of HF, ranging from the
prevention and treatment of congestion, and hence rehospi-
talization, to the improvement in symptoms and skeletal
muscle function to beneficial cardiac remodeling, improve-
ment in cardiac function, and enhanced prognosis.7
The study by Lee et al14 suggests that the implementation
of diagnostic examinations and evidence-based therapies by
the PC physician and the cardiologist may favorably affect
outcomes.1,5,7,18 The importance of the components of the
post-discharge assessment, suggested in the Table, will have
to be examined by future studies, since they have not been
tested in the post-discharge phase. Their application in
clinical practice may successfully turn the hospitalization for
HF from an ominous event heralding a poor prognosis to an
opportunity to improve patient outcomes through education,
correction of pathogenetic mechanisms and implementation
of evidence based therapies.
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